

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DMB

Display Date	3-1-00
Publication Date	3-2-00
Certifier	S. Keese

Food and Drug Administration

**Urology Subcommittee of the Advisory Committee for Reproductive Health Drugs;
Notice of Meeting**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Urology Subcommittee of the Advisory Committee for Reproductive Health Drugs

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on April 10, 2000, 9 a.m. to 5 p.m.


Location: Holiday Inn, Versailles Ballrooms, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Sandra Titus or Jayne E. Peterson or Robin M. Spencer, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or e-mail: TITUSS@CDER.FDA.GOV, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12537. Please call the Information Line for up-to-date information on this meeting.

Agenda: The subcommittee will consider the safety and efficacy of new drug application 21-118, Uprima™ (apomorphine HCl tablets, sublingual, TAP Holdings) proposed for use in the treatment of erectile dysfunction.

Procedure: Interested persons may present data, information, or views, orally or in writing on issues pending before the subcommittee. Written submissions may be made to the contact person


by April 5, 2000. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before April 5, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.



Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.

2).

Dated: February 18, 2000

A handwritten signature in cursive script, reading "Linda A. Suydam", written over a horizontal line.

Linda A. Suydam
Senior Associate Commissioner

[FR Doc. 00-???? Filed ??-??-00; 8:45 am]

BILLING CODE 4160-01-F

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

A handwritten signature in cursive script, reading "Sybil V. Reese".